BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 16893075)

  • 1. Complement activation during sepsis in humans.
    Schreiber H; Rittirsch D; Flierl M; Brueckner U; Schneider M; Weiss M; Gebhard F; Huber-Lang M
    Adv Exp Med Biol; 2006; 586():217-26. PubMed ID: 16893075
    [No Abstract]   [Full Text] [Related]  

  • 2. In response to complement anaphylatoxin peptides C3a and C5a, human vascular endothelial cells migrate and mediate the activation of B-cells and polarization of T-cells.
    Shivshankar P; Li YD; Mueller-Ortiz SL; Wetsel RA
    FASEB J; 2020 Jun; 34(6):7540-7560. PubMed ID: 32301538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New concepts on the therapeutic control of complement anaphylatoxin receptors.
    Hawksworth OA; Li XX; Coulthard LG; Wolvetang EJ; Woodruff TM
    Mol Immunol; 2017 Sep; 89():36-43. PubMed ID: 28576324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Food intake regulation by central complement system.
    Ohinata K; Yoshikawa M
    Adv Exp Med Biol; 2008; 632():35-46. PubMed ID: 19025112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors.
    Oppermann M; Götze O
    Immunology; 1994 Aug; 82(4):516-21. PubMed ID: 7835913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human plasmacytoid dendritic cells express receptors for anaphylatoxins C3a and C5a and are chemoattracted to C3a and C5a.
    Gutzmer R; Köther B; Zwirner J; Dijkstra D; Purwar R; Wittmann M; Werfel T
    J Invest Dermatol; 2006 Nov; 126(11):2422-9. PubMed ID: 16778800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement Activation in Arterial and Venous Thrombosis is Mediated by Plasmin.
    Foley JH; Walton BL; Aleman MM; O'Byrne AM; Lei V; Harrasser M; Foley KA; Wolberg AS; Conway EM
    EBioMedicine; 2016 Mar; 5():175-82. PubMed ID: 27077125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement peptides and mast cell triggering.
    Erdei A; Pecht I
    Immunol Lett; 1996 Dec; 54(2-3):109-12. PubMed ID: 9052863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement in sepsis-when science meets clinics.
    Mollnes TE; Huber-Lang M
    FEBS Lett; 2020 Aug; 594(16):2621-2632. PubMed ID: 32621378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.
    Rinder CS; Rinder HM; Smith BR; Fitch JC; Smith MJ; Tracey JB; Matis LA; Squinto SP; Rollins SA
    J Clin Invest; 1995 Sep; 96(3):1564-72. PubMed ID: 7657827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement C5a Functions as a Master Switch for the pH Balance in Neutrophils Exerting Fundamental Immunometabolic Effects.
    Denk S; Neher MD; Messerer DAC; Wiegner R; Nilsson B; Rittirsch D; Nilsson-Ekdahl K; Weckbach S; Ignatius A; Kalbitz M; Gebhard F; Weiss ME; Vogt J; Radermacher P; Köhl J; Lambris JD; Huber-Lang MS
    J Immunol; 2017 Jun; 198(12):4846-4854. PubMed ID: 28490576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model.
    Shao Z; Nishimura T; Leung LL; Morser J
    J Thromb Haemost; 2015 Jun; 13(6):1090-102. PubMed ID: 25851247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil extracellular traps can activate alternative complement pathways.
    Wang H; Wang C; Zhao MH; Chen M
    Clin Exp Immunol; 2015 Sep; 181(3):518-27. PubMed ID: 25963026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of C3a and C5a in hyperacute rejection of guinea pig-to-rat cardiac xenografts.
    Pruitt SK; Baldwin WM; Sanfilippo F
    Transplant Proc; 1996 Apr; 28(2):596. PubMed ID: 8623292
    [No Abstract]   [Full Text] [Related]  

  • 15. Differential effects of complement activation products c3a and c5a on cardiovascular function in hypertensive pregnant rats.
    Lillegard KE; Loeks-Johnson AC; Opacich JW; Peterson JM; Bauer AJ; Elmquist BJ; Regal RR; Gilbert JS; Regal JF
    J Pharmacol Exp Ther; 2014 Nov; 351(2):344-51. PubMed ID: 25150279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a.
    Chen NJ; Mirtsos C; Suh D; Lu YC; Lin WJ; McKerlie C; Lee T; Baribault H; Tian H; Yeh WC
    Nature; 2007 Mar; 446(7132):203-7. PubMed ID: 17322907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement factors and their receptors.
    Ember JA; Hugli TE
    Immunopharmacology; 1997 Dec; 38(1-2):3-15. PubMed ID: 9476110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel interpretation of immune redundancy and duality in reperfusion injury with important implications for intervention in ischaemic disease.
    Thrane AS; Skehan JD; Thrane PS
    Med Hypotheses; 2007; 68(6):1363-70. PubMed ID: 17169498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement C5a in the sepsis syndrome--too much of a good thing?
    Gerard C
    N Engl J Med; 2003 Jan; 348(2):167-9. PubMed ID: 12519929
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of the complement anaphylatoxins in the recruitment of eosinophils.
    DiScipio RG; Schraufstatter IU
    Int Immunopharmacol; 2007 Dec; 7(14):1909-23. PubMed ID: 18039528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.